Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes

Jun Sing Wang, Yi Jen Hung, Yung Chuan Lu, Cheng Lin Tsai, Wei Shiung Yang, Ting I. Lee, Ya Chun Hsiao, Wayne Huey Herng Sheu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: We aimed to investigate the association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy in patients with type 2 diabetes (T2D). Methods: This was a prospective observational study. Adults ≥ 20 years old with T2D and HbA1c ≧7% treated with oral anti-diabetic drugs (OADs) were eligible if their OADs were shifted to vildagliptin-based dual oral therapy. Fasting plasma glucose (FPG) and HbA1c were recorded at baseline, week 12, and week 24. To determine baseline dopHbA1c, a predicted HbA1c was calculated by inserting baseline FPG into a regression equation (HbA1c = FPG ∗ 0.0225 + 4.3806) developed from linear relationship between HbA1c and FPG in an independent cohort of 3239 outpatients with T2D (dopHbA1c = observed HbA1c – predicted HbA1c). Patients were assigned to low (≦0) or high (>0) dopHbA1c group according to their baseline dopHbA1c levels. The study endpoint was changes from baseline to week 24 in HbA1c levels. Results: A total of 1224 patients were enrolled. Patients with a dopHbA1c >0 had a greater HbA1c reduction after vildagliptin-based dual oral therapy than those with a dopHbA1c ≦0 (−1.5 ± 2.0 vs. −0.4 ± 1.0%, p < 0.001). Baseline dopHbA1c was positively associated with HbA1c reduction from baseline to week 24 (β coefficient 0.883, 95% CI 0.811 to 0.955, p < 0.001), and the association remained significant after adjustment for confounders. Conclusions: In T2D patients with an HbA1c ≧7%, a higher baseline dopHbA1c was associated with a greater HbA1c reduction after shifting to vildagliptin-based dual oral therapy.

Original languageEnglish
Pages (from-to)119-127
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume138
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Fasting
Glucose
Therapeutics
Pharmaceutical Preparations
Observational Studies
Outpatients
vildagliptin
Prospective Studies

Keywords

  • Dipeptidyl peptidase-4 inhibitors
  • Glycated hemoglobin
  • Hemoglobin glycation index
  • Type 2 diabetes
  • Vildagliptin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes. / Wang, Jun Sing; Hung, Yi Jen; Lu, Yung Chuan; Tsai, Cheng Lin; Yang, Wei Shiung; Lee, Ting I.; Hsiao, Ya Chun; Sheu, Wayne Huey Herng.

In: Diabetes Research and Clinical Practice, Vol. 138, 01.04.2018, p. 119-127.

Research output: Contribution to journalArticle

Wang, Jun Sing ; Hung, Yi Jen ; Lu, Yung Chuan ; Tsai, Cheng Lin ; Yang, Wei Shiung ; Lee, Ting I. ; Hsiao, Ya Chun ; Sheu, Wayne Huey Herng. / Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes. In: Diabetes Research and Clinical Practice. 2018 ; Vol. 138. pp. 119-127.
@article{fad861bed5d3474bbf2309cf1d580b03,
title = "Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes",
abstract = "Aim: We aimed to investigate the association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy in patients with type 2 diabetes (T2D). Methods: This was a prospective observational study. Adults ≥ 20 years old with T2D and HbA1c ≧7{\%} treated with oral anti-diabetic drugs (OADs) were eligible if their OADs were shifted to vildagliptin-based dual oral therapy. Fasting plasma glucose (FPG) and HbA1c were recorded at baseline, week 12, and week 24. To determine baseline dopHbA1c, a predicted HbA1c was calculated by inserting baseline FPG into a regression equation (HbA1c = FPG ∗ 0.0225 + 4.3806) developed from linear relationship between HbA1c and FPG in an independent cohort of 3239 outpatients with T2D (dopHbA1c = observed HbA1c – predicted HbA1c). Patients were assigned to low (≦0) or high (>0) dopHbA1c group according to their baseline dopHbA1c levels. The study endpoint was changes from baseline to week 24 in HbA1c levels. Results: A total of 1224 patients were enrolled. Patients with a dopHbA1c >0 had a greater HbA1c reduction after vildagliptin-based dual oral therapy than those with a dopHbA1c ≦0 (−1.5 ± 2.0 vs. −0.4 ± 1.0{\%}, p < 0.001). Baseline dopHbA1c was positively associated with HbA1c reduction from baseline to week 24 (β coefficient 0.883, 95{\%} CI 0.811 to 0.955, p < 0.001), and the association remained significant after adjustment for confounders. Conclusions: In T2D patients with an HbA1c ≧7{\%}, a higher baseline dopHbA1c was associated with a greater HbA1c reduction after shifting to vildagliptin-based dual oral therapy.",
keywords = "Dipeptidyl peptidase-4 inhibitors, Glycated hemoglobin, Hemoglobin glycation index, Type 2 diabetes, Vildagliptin",
author = "Wang, {Jun Sing} and Hung, {Yi Jen} and Lu, {Yung Chuan} and Tsai, {Cheng Lin} and Yang, {Wei Shiung} and Lee, {Ting I.} and Hsiao, {Ya Chun} and Sheu, {Wayne Huey Herng}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.diabres.2018.02.002",
language = "English",
volume = "138",
pages = "119--127",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes

AU - Wang, Jun Sing

AU - Hung, Yi Jen

AU - Lu, Yung Chuan

AU - Tsai, Cheng Lin

AU - Yang, Wei Shiung

AU - Lee, Ting I.

AU - Hsiao, Ya Chun

AU - Sheu, Wayne Huey Herng

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Aim: We aimed to investigate the association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy in patients with type 2 diabetes (T2D). Methods: This was a prospective observational study. Adults ≥ 20 years old with T2D and HbA1c ≧7% treated with oral anti-diabetic drugs (OADs) were eligible if their OADs were shifted to vildagliptin-based dual oral therapy. Fasting plasma glucose (FPG) and HbA1c were recorded at baseline, week 12, and week 24. To determine baseline dopHbA1c, a predicted HbA1c was calculated by inserting baseline FPG into a regression equation (HbA1c = FPG ∗ 0.0225 + 4.3806) developed from linear relationship between HbA1c and FPG in an independent cohort of 3239 outpatients with T2D (dopHbA1c = observed HbA1c – predicted HbA1c). Patients were assigned to low (≦0) or high (>0) dopHbA1c group according to their baseline dopHbA1c levels. The study endpoint was changes from baseline to week 24 in HbA1c levels. Results: A total of 1224 patients were enrolled. Patients with a dopHbA1c >0 had a greater HbA1c reduction after vildagliptin-based dual oral therapy than those with a dopHbA1c ≦0 (−1.5 ± 2.0 vs. −0.4 ± 1.0%, p < 0.001). Baseline dopHbA1c was positively associated with HbA1c reduction from baseline to week 24 (β coefficient 0.883, 95% CI 0.811 to 0.955, p < 0.001), and the association remained significant after adjustment for confounders. Conclusions: In T2D patients with an HbA1c ≧7%, a higher baseline dopHbA1c was associated with a greater HbA1c reduction after shifting to vildagliptin-based dual oral therapy.

AB - Aim: We aimed to investigate the association of difference between observed and predicted glycated hemoglobin (dopHbA1c) and HbA1c reduction after vildagliptin-based oral therapy in patients with type 2 diabetes (T2D). Methods: This was a prospective observational study. Adults ≥ 20 years old with T2D and HbA1c ≧7% treated with oral anti-diabetic drugs (OADs) were eligible if their OADs were shifted to vildagliptin-based dual oral therapy. Fasting plasma glucose (FPG) and HbA1c were recorded at baseline, week 12, and week 24. To determine baseline dopHbA1c, a predicted HbA1c was calculated by inserting baseline FPG into a regression equation (HbA1c = FPG ∗ 0.0225 + 4.3806) developed from linear relationship between HbA1c and FPG in an independent cohort of 3239 outpatients with T2D (dopHbA1c = observed HbA1c – predicted HbA1c). Patients were assigned to low (≦0) or high (>0) dopHbA1c group according to their baseline dopHbA1c levels. The study endpoint was changes from baseline to week 24 in HbA1c levels. Results: A total of 1224 patients were enrolled. Patients with a dopHbA1c >0 had a greater HbA1c reduction after vildagliptin-based dual oral therapy than those with a dopHbA1c ≦0 (−1.5 ± 2.0 vs. −0.4 ± 1.0%, p < 0.001). Baseline dopHbA1c was positively associated with HbA1c reduction from baseline to week 24 (β coefficient 0.883, 95% CI 0.811 to 0.955, p < 0.001), and the association remained significant after adjustment for confounders. Conclusions: In T2D patients with an HbA1c ≧7%, a higher baseline dopHbA1c was associated with a greater HbA1c reduction after shifting to vildagliptin-based dual oral therapy.

KW - Dipeptidyl peptidase-4 inhibitors

KW - Glycated hemoglobin

KW - Hemoglobin glycation index

KW - Type 2 diabetes

KW - Vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=85042383785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042383785&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2018.02.002

DO - 10.1016/j.diabres.2018.02.002

M3 - Article

AN - SCOPUS:85042383785

VL - 138

SP - 119

EP - 127

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -